Close Menu

NEW YORK – ArcherDx said on Friday that it has signed a non-exclusive, multiyear partnership with Illumina intended to broaden access to next-generation sequencing oncology testing, including — upon regulatory approval — companion diagnostics for therapeutic selection, personalized monitoring, and new recurrence surveillance in vitro diagnostics.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.